Want to see PPCB full AI Analyst Report?
Top Page
Propanc Biopharma
(NASDAQ:PPCB)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.96
▲(334.09% Upside)
Action:Reiterated
Date:07/30/26
The score is held down primarily by very weak financial performance (minimal revenue, large recurring losses, and ongoing cash burn suggesting continued funding needs) and a clear negative price trend (trading well below all major moving averages). Valuation provides limited support due to a negative P/E tied to losses and no dividend signal. A positive board appointment offers a minor offset but is not enough to outweigh the fundamental and trend-related risks.
Positive Factors
Low Leverage / Balance Sheet Cushion
Reported debt is minimal versus equity, which reduces near-term solvency risk and interest burden. For a pre-commercial biotech, low leverage provides structural flexibility to raise R&D funding on more favorable terms and reduces immediate bankruptcy risk over the next 2–6 months.
Negative Factors
Minimal Commercial Revenue
Practically no product revenue demonstrates a fully pre-commercial profile, meaning the business lacks internal cash generation from sales. Over months this keeps the company dependent on external financing and makes operational continuity contingent on successful capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Cushion
Reported debt is minimal versus equity, which reduces near-term solvency risk and interest burden. For a pre-commercial biotech, low leverage provides structural flexibility to raise R&D funding on more favorable terms and reduces immediate bankruptcy risk over the next 2–6 months.
Read all positive factors
Propanc Biopharma (PPCB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.54M
Dividend YieldN/A
Average Volume (3M)400.33K
Price to Earnings (P/E)―
Beta (1Y)-0.97
Revenue GrowthN/A
EPS Growth98.95%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,503,116
10 Day Avg. Volume553,394
30 Day Avg. Volume400,327
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-40.64
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Propanc Biopharma Business Overview & Revenue Model
Company Description
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeuti...
How the Company Makes Money
null...
Propanc Biopharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
35
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -21.66K | -17.76K | -5.67K | 0.00 |
| EBITDA | -17.68M | -58.34M | -1.26M | -2.23M | -2.14M | -1.69M |
| Net Income | -18.36M | -58.92M | -1.82M | -2.66M | -2.66M | -2.03M |
Balance Sheet | ||||||
| Total Assets | 14.33M | 19.63M | 72.36K | 60.33K | 81.65K | 13.10K |
| Cash, Cash Equivalents and Short-Term Investments | 443.70K | 12.09K | 21.09K | 10.05K | 4.07K | 2.25K |
| Total Debt | 1.57M | 1.73M | 948.27K | 545.92K | 1.04M | 680.08K |
| Total Liabilities | 4.51M | 5.73M | 3.85M | 3.18M | 3.11M | 3.08M |
| Stockholders Equity | 9.83M | 13.91M | -3.78M | -3.12M | -3.02M | -3.07M |
Cash Flow | ||||||
| Free Cash Flow | -4.11M | -405.17K | -935.12K | -1.11M | -1.44M | -1.15M |
| Operating Cash Flow | -4.11M | -405.17K | -935.12K | -1.11M | -1.44M | -1.15M |
| Investing Cash Flow | -4.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 4.49M | 490.76K | 941.89K | 1.11M | 1.49M | 1.06M |
Propanc Biopharma Risk Analysis
Propanc Biopharma disclosed 51 risk factors in its most recent earnings report. Propanc Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Propanc Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
PPCB
Propanc Biopharma
1.01
-223.99
-99.55%
VRCA
Verrica Pharmaceuticals
5.22
-0.35
-6.28%
BRNS
Barinthus Biotherapeutics
0.56
-0.73
-56.82%
TELO
Telomir Pharmaceuticals, Inc.
1.21
-0.62
-33.88%
Propanc Biopharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Propanc Biopharma Appoints New Director to Board
Positive
Jul 15, 2026
On July 8, 2026, Propanc Biopharma director Annie Van Broekhoven retired and resigned from the company’s board, marking a change in its governance structure. The board immediately filled the vacancy by appointing qualified accountant Carlo C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.